Company Alligator Bioscience AB

Equities

ATORX

SE0000767188

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Group companies

Sector

Sales per region

Ratings for Alligator Bioscience AB

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 04:33:28 2024-04-25 am EDT			5-day change	1st Jan Change
0.922 ^SEK	+0.22%		-12.31%	+32.37%

Apr. 05	Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board	CI
Mar. 26	Alligator Bioscience Announces Publication of a Scientific Article Featuring Its Novel Bispecific Antibody Format RUBY® in the Peer-Reviewed Journal mAbs	CI

Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligatorâs pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.

Number of employees: 58

SEK in Million	2022	Weight	2023	Weight	Delta
Antibody-based Medicines 100.0 %	36	100.0 %	58	100.0 %	+62.78%

SEK in Million	2022	Weight	2023	Weight	Delta
Finland 100.0 %	36	100.0 %	58	100.0 %	+62.78%

Managers	Title	Age	Since
Søren Bregenholt CEO	Chief Executive Officer	53	21-05-31
Marie Svensson DFI	Director of Finance/CFO	60	20-08-31
Sumeet Ambarkhane CTO	Chief Tech/Sci/R&D Officer	56	22-01-31
Peter Ellmark CTO	Chief Tech/Sci/R&D Officer	51	17-12-31
Laura Ila von Schantz CTO	Chief Tech/Sci/R&D Officer	42	13-12-31

Members of the board	Title	Age	Since
Graham Dixon BRD	Director/Board Member	63	19-05-08
Anders Olof Adolf Ekblom CHM	Chairman	70	16-12-31
Staffan Encrantz BRD	Director/Board Member	73	22-05-08
Anette Sundstedt BRD	Director/Board Member	57	20-12-31
Eva Ulrika Sjökvist Saers BRD	Director/Board Member	62	21-05-31
Denise Goode BRD	Director/Board Member	66	22-05-08
Hans-Peter Albert Ostler BRD	Director/Board Member	53	21-05-31
Veronica Wallin BRD	Director/Board Member	38	21-05-31
Laura Ila von Schantz CTO	Chief Tech/Sci/R&D Officer	42	13-12-31
Eva Sjökvist Saers		62	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	949,850	0	0	61.47 %
Stock B	1	657,954,290	405,056,473 ( 61.56 %)	0

Name	Equities	%	Valuation
Allegro Investment, Inc. 31.28 %	205,840,049	31.28 %	19 M kr
Roxette Photo NV 8.123 %	53,446,475	8.123 %	5 M kr
Magnus Petersson 2.907 %	19,124,338	2.907 %	2 M kr
NORDNET AB 2.506 %	16,490,783	2.506 %	2 M kr
Johan Zetterstedt 1.664 %	10,945,303	1.664 %	1 M kr
Lars Spanberg 1.465 %	9,641,572	1.465 %	896 281 kr
Lennart Erik Jonas Sjögren 1.026 %	6,753,098	1.026 %	627 768 kr
Sunstone Capital A/S 0.8752 %	5,758,485	0.8752 %	535 309 kr
Mikael Lönn 0.6576 %	4,326,547	0.6576 %	402 196 kr
Pearla Gem Ltd. 0.6287 %	4,136,681	0.6287 %	384 546 kr

Alligator Bioscience AB

Medicon Village Scheelevägen 2

223 81, Lund

+46 4 65 40 82 00

http://www.alligatorbioscience.com

Name	Category and Sector
A Bioscience Incentive AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.92 SEK

Average target price

2.3 SEK

Spread / Average Target

+150.00%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALLIGATOR BIOSCIENCE AB	+32.37%	64.04M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+46.73%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research